234 related articles for article (PubMed ID: 34569906)
1. Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.
Zheng Y; Kong F; Liu S; Liu X; Pei D; Miao X
Drug Deliv; 2021 Dec; 28(1):2033-2043. PubMed ID: 34569906
[TBL] [Abstract][Full Text] [Related]
2. Homotypic cell membrane-camouflaged biomimetic PLGA nanoparticle loading triptolide for the treatment of hepatocellular carcinoma.
Li Z; Lan J; Wu Y; Ding Y; Zhang T
Drug Deliv; 2024 Dec; 31(1):2354687. PubMed ID: 38823413
[TBL] [Abstract][Full Text] [Related]
3. Triptolide Inhibits Invasion and Tumorigenesis of Hepatocellular Carcinoma MHCC-97H Cells Through NF-κB Signaling.
Wang H; Ma D; Wang C; Zhao S; Liu C
Med Sci Monit; 2016 May; 22():1827-36. PubMed ID: 27239780
[TBL] [Abstract][Full Text] [Related]
4. Self-Amplified pH/ROS Dual-Responsive Co-Delivery Nano-System with Chemo-Photodynamic Combination Therapy in Hepatic Carcinoma Treatment.
Huang Y; Wu S; Li J; He C; Cheng Y; Li N; Wang Y; Wu Y; Zhang J
Int J Nanomedicine; 2024; 19():3737-3751. PubMed ID: 38699684
[TBL] [Abstract][Full Text] [Related]
5. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer.
Yalikong A; Li XQ; Zhou PH; Qi ZP; Li B; Cai SL; Zhong YS
Int J Nanomedicine; 2021; 16():2323-2335. PubMed ID: 33776436
[TBL] [Abstract][Full Text] [Related]
6. Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase.
Lin Y; Peng N; Li J; Zhuang H; Hua ZC
Mol Cancer; 2013 Jun; 12():54. PubMed ID: 23758884
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma.
Li Z; Yang G; Han L; Wang R; Gong C; Yuan Y
J Nanobiotechnology; 2021 Nov; 19(1):360. PubMed ID: 34749742
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Alsaied OA; Sangwan V; Banerjee S; Krosch TC; Chugh R; Saluja A; Vickers SM; Jensen EH
Surgery; 2014 Aug; 156(2):270-9. PubMed ID: 24953273
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumour effects of triptolide plus 10-hydroxycamptothecin onbladder cancer.
Wang T; Ding Y; Yang Y; Wang Z; Gao W; Li D; Wei J; Sun Y
Biomed Pharmacother; 2019 Jul; 115():108899. PubMed ID: 31063955
[TBL] [Abstract][Full Text] [Related]
10. Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1.
Dai H; Jiang Y; Luo Y; Bie P; Chen Z
Phytomedicine; 2019 Sep; 62():152953. PubMed ID: 31128486
[TBL] [Abstract][Full Text] [Related]
11. Triptolide triggers the apoptosis of pancreatic cancer cells via the downregulation of Decoy receptor 3 expression.
Wang W; Li X; Sun W; Zhang L; Zhang M; Hong B; Lv G
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1597-605. PubMed ID: 22581262
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma.
Tang XY; Zhu YQ; Tao WH; Wei B; Lin XL
Postgrad Med J; 2007 May; 83(979):338-43. PubMed ID: 17488865
[TBL] [Abstract][Full Text] [Related]
13. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma.
Ling D; Xia H; Park W; Hackett MJ; Song C; Na K; Hui KM; Hyeon T
ACS Nano; 2014 Aug; 8(8):8027-39. PubMed ID: 25093274
[TBL] [Abstract][Full Text] [Related]
14. Triptolide induces S phase arrest via the inhibition of cyclin E and CDC25A and triggers apoptosis via caspase- and mitochondrial-dependent signaling pathways in A375.S2 human melanoma cells.
Hung FM; Chen YL; Huang AC; Hsiao YP; Yang JS; Chung MT; Chueh FS; Lu HF; Chung JG
Oncol Rep; 2013 Mar; 29(3):1053-60. PubMed ID: 23314229
[TBL] [Abstract][Full Text] [Related]
15. Triptolide inhibits tumor growth by induction of cellular senescence.
Li R; Zhang X; Tian X; Shen C; Zhang Q; Zhang Y; Wang Z; Wang F; Tao Y
Oncol Rep; 2017 Jan; 37(1):442-448. PubMed ID: 27878302
[TBL] [Abstract][Full Text] [Related]
16. C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells.
Li SG; Shi QW; Yuan LY; Qin LP; Wang Y; Miao YQ; Chen Z; Ling CQ; Qin WX
J Exp Clin Cancer Res; 2018 Mar; 37(1):51. PubMed ID: 29523159
[TBL] [Abstract][Full Text] [Related]
17. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms.
Zhang YQ; Shen Y; Liao MM; Mao X; Mi GJ; You C; Guo QY; Li WJ; Wang XY; Lin N; Webster TJ
Nanomedicine; 2019 Jan; 15(1):86-97. PubMed ID: 30244085
[TBL] [Abstract][Full Text] [Related]
18. Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
Lin Y; Yang X; Lu M; Zheng W; Zhang J; Zhuang H; Hua ZC
Anticancer Drugs; 2013 Oct; 24(9):945-57. PubMed ID: 23958791
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
Yang Y; Zhang LJ; Bai XG; Xu HJ; Jin ZL; Ding M
Biomed Pharmacother; 2018 Oct; 106():1307-1316. PubMed ID: 30119201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
